StockData
Prestige Consumer Healthcare Inc. logo

Prestige Consumer Healthcare Inc. (PBH) stock analysis

PBHNYSEPharmaceutical PreparationsFiscal year ends March 31
Financials through Q2 FY2027, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 11/3029% below fair value
$46.19+0.87 (+1.92%)

Close on Nov 13, 2026Market cap $2.19BP/E 14.3Yield –

StockData Score

Prices as of Nov 13, 2026How the score works

Value5Growth1Performance3Health2Dividend0

Mixed11 of 30 checks passed

Prestige Consumer Healthcare passes 11 of the 30 checks behind our score; 7 could not be run for lack of data and count as not passed. Each dot in the shape is one check — hover it for the numbers.

Valuation
5/6
Growth
1/6
Past performance
3/6
Financial health
2/6
Dividend
0/6

What stands out

  • Margin of safety over 20%

    The price is 29.2% below fair value, more than the 20% cushion we look for.

  • Trading below fair value

    The share price of $46.19 is below our fair value estimate of $65.23.

  • Earnings grew over 5 years

    Net income grew 2.9% a year on average over the last five fiscal years.

  • P/E below its 5-year median

    Prestige Consumer Healthcare's P/E of 14.3 is below its own 5-year median of 15.3.

What to watch

  • Return on equity under 15%

    Return on equity was 8.2% over the last twelve months and averaged 8.9% over five years; we look for 15% on both.

  • Return on capital under 10%

    Return on invested capital was 8.1%, below the 10% that usually covers the cost of capital.

  • High debt

    Debt is 107% of shareholders' equity, above the 40% we consider low.

  • Revenue growing under 10% a year

    Revenue grew -1.2% a year over the last three fiscal years, short of the 10% we look for.

Valuation5/6
  • P/E below its 5-year median

    Prestige Consumer Healthcare's P/E of 14.3 is below its own 5-year median of 15.3.

  • P/E below the industry

    Prestige Consumer Healthcare's P/E of 14.3 is below the Drugs median of 25.0.

  • EV/EBITDA above its 5-year median

    Prestige Consumer Healthcare's EV/EBITDA of 12.9 is above its 5-year median of 12.2.

  • P/B below the industry

    Prestige Consumer Healthcare's price-to-book of 1.13 is below the Drugs median of 2.09.

  • Trading below fair value

    The share price of $46.19 is below our fair value estimate of $65.23.

  • Margin of safety over 20%

    The price is 29.2% below fair value, more than the 20% cushion we look for.

Growth1/6
  • Revenue growing under 10% a year

    Revenue grew -1.2% a year over the last three fiscal years, short of the 10% we look for.

  • EPS growth over 3 years

    Needs positive EPS three years ago and today.

  • Earnings growth not accelerating

    Net income grew -22.8% over the last twelve months, against a 5-year average of 2.9% a year.

  • Growing slower than the industry

    Revenue grew 5.1% over the last twelve months; the Drugs median is 7.7%.

  • Guidance raised

    Prestige Consumer Healthcare raised its Projected FY'27 Projected FY'27 GAAP Net cash provided by operating activities outlook on Aug 6, 2026.

  • Gross margin slipping

    Gross margin was 52.5% over the last twelve months, against 56.1% a year earlier.

Past performance3/6
  • Return on equity under 15%

    Return on equity was 8.2% over the last twelve months and averaged 8.9% over five years; we look for 15% on both.

  • Return on capital under 10%

    Return on invested capital was 8.1%, below the 10% that usually covers the cost of capital.

  • Return on equity above the industry

    Prestige Consumer Healthcare's return on equity of 8.2% is above the Drugs median of -57.0%.

  • Earnings grew over 5 years

    Net income grew 2.9% a year on average over the last five fiscal years.

  • Net margin below its 5-year average

    Net margin was 13.3% over the last twelve months, against a 5-year average of 13.3%.

  • Net margin above the industry

    Prestige Consumer Healthcare's net margin of 13.3% is above the Drugs median of -53.5%.

Financial health2/6
  • High debt

    Debt is 107% of shareholders' equity, above the 40% we consider low.

  • Debt falling against equity

    Debt to equity fell from 109% five years ago to 107%.

  • Debt not well covered by cash flow

    Operating cash flow over the last twelve months equals 11.1% of total debt; we look for at least 20%.

  • Interest coverage

    Interest expense is not reported separately.

  • Short-term assets cover short-term debts

    Current assets are 2.92 times current liabilities.

  • Elevated bankruptcy risk

    The Altman Z-score is 1.54; above 3 is the safe zone and below 1.8 the distress zone.

Dividend0/6
  • No dividend

    Prestige Consumer Healthcare has not paid a dividend in the last twelve months.

  • Yield against Treasuries

    No dividend.

  • Yield against the market

    No dividend.

  • Dividend stability

    No dividend.

  • Earnings cover

    No dividend.

  • Cash-flow cover

    No dividend.

Scores of similar companies

Our estimate per share

$65.23

The share price is 29% below this estimate.

20%+ below
Near fair value
20%+ above
$46.19Price$65.23Fair value
MethodMultiple usedOwn 5Y medianIndustry medianValue per shareWeight
P/E20.1×15.3×25.0×$65.1140%
EV/EBITDA14.8×12.2×17.4×$59.4235%
P/B2.0×1.9×2.1×$82.6310%
Earnings power7.6% cost of equity––$67.5015%
Fair value$65.23100%

Valuation over time

Using the earnings and balance sheet published at each date, not today's.

  • P/E at month end
  • Own 5-year median 15.3
  • Drugs median 25.0

An estimate from reported numbers and market multiples, not a price target or investment advice. It can be far off for companies whose profits are about to change sharply.

Market risk

From the past year of daily prices.

Liquidity

Low risk

Average value traded per day
$28.42M
Value traded per 1% price move
$14.09M

Downside

Medium risk

Typical loss in a bad month
19.1%
Volatility (annualized)
38%
Sharpe ratio, 1 year
-0.75
Beta to the S&P 500 (5Y)
0.44

Typical bad-month loss, week by week

25%: high

Margins

Share of revenue, fiscal years 2012 to 2026

Gross margin

54.7%−3.3 pts over 5 years

Operating margin

28.4%−3.1 pts over 5 years

Net margin

17.5%+0.0 pts over 5 years

See a number that looks wrong?